Evidence map›Paper›PMID 36164273›Full record

SynthesisCancer medicine2023

Increased lncRNA AFAP1-AS1 expression predicts poor prognosis in gastric cancer: Evidence from published studies and followed up verification.

Fujiao Duan, Yilin Li, Yajing Feng, Guanghui Niu, Junhui Chai, Kaijuan Wang

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fujiao DuanDepartment of Medical Research Office and General Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0000-0002-5731-5463
Yilin LiDepartment of Medical Research Office and General Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yajing FengDepartment of Nosocomial Infection Management, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guanghui NiuDepartment of Medical Research Office and General Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Junhui ChaiDepartment of Medical Research Office and General Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Kaijuan WangKey Laboratory of Tumor Epidemiology of Henan Province, Zhengzhou, Henan, China.ORCID 0000-0002-3300-9453
Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe purpose of this study was to clarify the influence of long non-coding RNA actin fiber-associated protein-1 antisense RNA 1 (lncRNA AFAP1-AS1) on the prognosis of gastric cancer (GC).

methodsBased on meta-analysis, the association between the expression of AFAP1-AS1 and the prognosis of GC was estimated. GC tissue and non-cancer tissues from 136 patients were determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and verified by Gene Expression Profiling Interactive Analysis (GEPIA). Kaplan-Meier and Cox proportional hazards models were conducted to analyze the correlation between AFAP1-AS1 expression and GC prognosis.

resultsThe pooled analysis from five studies revealed that the AFAP1-AS1 expression was significantly associated with GC overall survival (hazard ratio (HR) = 2.49 and 95% confidence interval (95% CI): 2.02-3.08, p  <  0.001). Compared with non-cancer tissues, AFAP1-AS1 expression level of GC tissues were significantly upregulated (p  <  0.001), which was confirmed by the results of GEPIA. The area under the receiver-operating characteristic (ROC) curve was 0.893, and the high expression of AFAP1-AS1 was correlated with poor prognosis in patients with GC (p = 0.005). Clinical grade (HR = 1.912, 95% CI: 1.246-2.934, p = 0.003), pathologic tumor node metastasis (pTNM) (HR = 2.393, 95% CI: 1.431-4.033, p = 0.001), log odds of positive lymph nodes (LODDS) (HR = 2.910, 95% CI: 1.787-4.793, p  <  0.001) and AFAP1-AS1 expression (HR = 2.393, 95% CI: 1.869-3.064, p  <   0.001) were independent prognostic factors for GC revealed by multivariate Cox-regression analysis.

conclusionThis study demonstrated that the AFAP1-AS1 may be a novel biomarker for the diagnosis and prognosis of GC.

Indexed as

RNA, Long NoncodingStomach NeoplasmsHumansPrognosisProportional Hazards ModelsRNA, Long NoncodingAFAP1-AS1gastric cancerlncRNAmeta-analysisprognosis

Identifiers

PMID36164273
PMCPMC9972132
OpenAlexW4297256211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.